China SXT Pharmaceuticals, Inc.
SXTC
$1.08
-$0.045-4.02%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -22.23% | -22.23% | -51.52% | -51.52% | 17.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.23% | -22.23% | -51.52% | -51.52% | 17.57% |
| Cost of Revenue | -41.78% | -41.78% | -34.03% | -34.03% | 58.94% |
| Gross Profit | 221.88% | 221.88% | -63.71% | -63.71% | -72.35% |
| SG&A Expenses | 677.08% | 677.08% | 37.77% | 37.77% | -61.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 336.18% | 336.18% | 25.77% | 25.77% | -39.81% |
| Operating Income | -712.67% | -712.67% | -78.73% | -78.73% | 60.22% |
| Income Before Tax | -548.75% | -548.75% | -68.06% | -68.06% | 45.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -548.75% | -548.75% | -67.92% | -67.92% | 51.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -548.75% | -548.75% | -67.92% | -67.92% | 51.66% |
| EBIT | -712.67% | -712.67% | -78.73% | -78.73% | 60.22% |
| EBITDA | -788.72% | -788.72% | -83.32% | -83.32% | 61.55% |
| EPS Basic | -32.36% | -32.36% | 79.74% | 79.74% | 85.31% |
| Normalized Basic EPS | -32.37% | -32.37% | 81.32% | 81.32% | 83.58% |
| EPS Diluted | -32.36% | -32.36% | 79.74% | 79.74% | 85.31% |
| Normalized Diluted EPS | -32.37% | -32.37% | 81.32% | 81.32% | 83.58% |
| Average Basic Shares Outstanding | 390.22% | 390.22% | 728.41% | 728.41% | 228.94% |
| Average Diluted Shares Outstanding | 390.22% | 390.22% | 728.41% | 728.41% | 228.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
